Deanna Herbert1, Maria Neves-Pereira1, Ruth Baidya1, Sheraz Cheema1, Sarah Groleau1, Anashe Shahmirian1, Arun K Tiwari2, Clement C Zai3, Nicole King1, Daniel J Müller4, James L Kennedy5. 1. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Molecular Brain Science Research Department, Centre for Addiction and Mental Health, Toronto, ON, Canada. 2. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Molecular Brain Science Research Department, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada. 3. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Molecular Brain Science Research Department, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Laboratory Medicine & Pathobiology, University of Toronto, Toronto, ON, Canada. 4. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Molecular Brain Science Research Department, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada. 5. Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Molecular Brain Science Research Department, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada. Electronic address: jim.kennedy@camh.ca.
Abstract
OBJECTIVE: Pharmacotherapy is one of the primary treatments for psychiatric disorders. Given the variation in individual response, a more personalized approach is needed. This paper will discuss methods for user-friendly referrals, recruitment criteria, data storage and dissemination, biological sample and clinical questionnaire collection, and advertising. METHODS: The Individualized Medicine: Pharmacogenetics Assessment and Clinical Treatment (IMPACT) study is one of the first to use pharmacogenetic testing on a large scale in psychiatry as a tool to predict individual drug response and tolerability. As IMPACT's eligibility criteria includes all diagnoses and comorbidities, the participant population will reflect the diversity amongst mental health consumers. IMPACT's innovative study design will demonstrate the utility of this testing within the health care system. RESULTS: IMPACT has successfully implemented pharmacogenetic testing on a relatively large scale, and in both tertiary level and primary care settings. It represents a novel approach to psychiatric care and from its initial stages the design has evolved to accommodate the nature and needs of the health care community. CONCLUSION: It is anticipated that IMPACT will continue to demonstrate the feasibility of pharmacogenetic testing and facilitate its introduction and implementation in routine healthcare practice.
OBJECTIVE: Pharmacotherapy is one of the primary treatments for psychiatric disorders. Given the variation in individual response, a more personalized approach is needed. This paper will discuss methods for user-friendly referrals, recruitment criteria, data storage and dissemination, biological sample and clinical questionnaire collection, and advertising. METHODS: The Individualized Medicine: Pharmacogenetics Assessment and Clinical Treatment (IMPACT) study is one of the first to use pharmacogenetic testing on a large scale in psychiatry as a tool to predict individual drug response and tolerability. As IMPACT's eligibility criteria includes all diagnoses and comorbidities, the participant population will reflect the diversity amongst mental health consumers. IMPACT's innovative study design will demonstrate the utility of this testing within the health care system. RESULTS: IMPACT has successfully implemented pharmacogenetic testing on a relatively large scale, and in both tertiary level and primary care settings. It represents a novel approach to psychiatric care and from its initial stages the design has evolved to accommodate the nature and needs of the health care community. CONCLUSION: It is anticipated that IMPACT will continue to demonstrate the feasibility of pharmacogenetic testing and facilitate its introduction and implementation in routine healthcare practice.
Authors: Cathy R Fulton; Marelize Swart; Thomas De Luca; Stephanie N Liu; Kimberly S Collins; Zeruesenay Desta; Brandon T Gufford; Michael T Eadon Journal: J Nurse Pract Date: 2018-11-02 Impact factor: 0.767
Authors: Lindsay M Melhuish Beaupre; Vanessa F Gonçalves; Clement C Zai; Arun K Tiwari; Ricardo S Harripaul; Deanna Herbert; Natalie Freeman; Daniel J Müller; James L Kennedy Journal: Mol Neuropsychiatry Date: 2020-01-08
Authors: Mary E Kelley; Ki Sueng Choi; Justin K Rajendra; W Edward Craighead; Jeffrey J Rakofsky; Boadie W Dunlop; Helen S Mayberg Journal: Biol Psychiatry Date: 2021-02-26 Impact factor: 12.810
Authors: Clement C Zai; Arun K Tiwari; Gwyneth C Zai; Natalie Freeman; Jennie G Pouget; James Greco; Maria Tampakeras; Sajid A Shaikh; Deanna Herbert; Heather Emmerson; Sheraz Y Cheema; Nicole Braganza; Daniel J Müller; Aristotle N Voineskos; Gary Remington; James L Kennedy Journal: Front Pharmacol Date: 2019-11-26 Impact factor: 5.810
Authors: Joseph O'Shea; Mark Ledwidge; Joseph Gallagher; Catherine Keenan; Cristín Ryan Journal: Pharmacogenomics J Date: 2022-02-22 Impact factor: 3.245
Authors: Clement C Zai; Frankie H Lee; Arun K Tiwari; Justin Y Lu; Vincenzo de Luca; Miriam S Maes; Deanna Herbert; Anashe Shahmirian; Sheraz Y Cheema; Gwyneth C Zai; Anupama Atukuri; Michael Sherman; Sajid A Shaikh; Maria Tampakeras; Natalie Freeman; Nicole King; Daniel J Müller; Lior Greenbaum; Bernard Lerer; Aristotle N Voineskos; Steven G Potkin; Jeffrey A Lieberman; Herbert Y Meltzer; Gary Remington; James L Kennedy Journal: Front Pharmacol Date: 2018-09-18 Impact factor: 5.810